Navigation Links
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings

HASBROUCK HEIGHTS, NJ (June 21, 2007) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that detailed results from the Company’s recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meetings, beginning in September at the South Central American Urological Association Meeting in Colorado Springs. These independent podium presentations will be given by leading clinical research urologist principal investigators from the clinical trials. Further specific details on the upcoming presentations will be announced at a later date.

The Company has completed a series of studies of the safety and efficacy of NX-1207 for BPH, including two Phase 1-2 studies and a Phase 2 study as well as several follow-up studies of patients for up to 3 ½ years after NX-1207 treatment. The Company’s recently completed prospective randomized placebo controlled Phase 2 U.S. study confirmed the positive efficacy and safety results for NX-1207 from earlier studies. After 3 months, patients treated with NX-1207 had a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement was significantly greater than the 3.5 to 5 points typically reported for currently approved drugs for BPH. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. In particular, patients given NX-1207 had no (0%) significant sexual side effects. Follow-up studies have provided data showing that NX-1207 can provide enduring benefits of up to 42 months or more following treatment.

The AUA Symptom Score is a standardized and widely accepted questionnaire used to assess the severity of BPH symptoms and the efficacy of treatments for BPH. The AUA Score consists of seven questions relating to frequency of problems with urination such a
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
2. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
3. Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH
4. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nymox Announces Data Presented Upcoming Urology Meetings
(Date:11/24/2009)...swire/--SatelliteHealthcare,oneofthenation,sfirsta...rsponsorofnephrologyresearch,todayannounceditsfull...inhisefforttosupporttheSanJosehomelessthisThanksgi...areerasachefforthepast20years.ButNasrallah,slifewa...ithEndStageRenalDisease(ESRD).Thediagnosisirrevoca...
(Date:11/24/2009)...Call/--OptimerPharmaceuticals,Inc.(Nasdaq: OPTR )i...thCareConferenceatTheNewYorkPalaceinNewYorkCityonD...ttp://www.newscom.com/cgi-bin/prnh/20090413/LA9735...illbeaccessibleontheInvestorspageoftheCompany,sweb...ntationwillbeavailableatthesamelocationfor30daysfo...
(Date:11/24/2009)...FirstCall/--BioSpecificsTechnologiesCorp.(Nasdaq: ...lasscollagenase-basedproducts,todayannouncedthatBi...omingPiperJaffray21stAnnualHealthCareConferenceonT...HotelinNewYork,NY. ,, Alivewebcastofthepresenta...torRelationssectionoftheCompany,swebsiteat www.bio...
Breaking Medicine Technology:Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 2Henry Ford Macomb Hospital Deploys PerfectServe at Warren Campus to Improve Communication Better Coordinate Care 58519 1Henry Ford Macomb Hospital Deploys PerfectServe at Warren Campus to Improve Communication Better Coordinate Care 58519 2Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 1Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 2Harris Corporation Demonstrates Secure Exchange of Public Health Information in Cloud Computing Environment 58517 3Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 1Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 2
...SIA, Pa., March 31 Successful and seamless comple... forecasting of screened to randomized patients, m... and project management guided by real time metric...ch notes: "This is achievable when clinical trial ..." She adds, "We had great team chemistry with the ...
...ich., March 31 QuatRx Pharmaceuticals, a privat...d that it has completed enrollment in the Company,...(TM) (ospemifene tablets). Together with the prev...phena(TM) , the Company has fully enrolled its pla... most advanced estrogen-free oral therapy currentl...
Other Medicine Technology:Major Restless Legs Study Completes Enrollment With Support From MediciGlobal 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 3
(Date:11/25/2009)...r basketball organization has selected a full rost...apy, technology, and learning as part of their vis...t Center. After a year of research and evaluation,...aquatic training; the selection of flagship hydrot...HydroWorx 2000 Series, an elite training tool, pac...
(Date:11/25/2009)...eamHealer,s GlobalIntentionHealsProjectprovedthats...neatadistance.Over10,000participantssenthealingint...aquantitative-EEG.Thedatawasanalyzedbyworldexperts...C.Adaminitiatedtheworld,slargestintentionalhealing...ofaspecificvisualizationtobeusedbyallparticipants,...
(Date:11/24/2009)...de accurate preliminary interpretation of emergenc...ng neuroradiologist unavailable, according to resu... center published in the December issue of the Jo... ). , The accuracy of image interpretation is t... In most training programs, radiology residents pr...
(Date:11/24/2009)...wire/--OnFriday,November20,juniorfeatherweightboxe...adduringatitleboutinPhiladelphia.HewasrushedtoHahn...onducted,hewasdeclaredbraindeadonSunday. ,, Gif...rganization(OPO)servingeasternPennsylvania,souther...partofstandardclinicalprocedurestodetermineifFranc...
(Date:11/24/2009)...re/--SkyFoundation,Inc.,anon-profitfoundationdedic...testfortheearlydetectionofpancreaticcancer,todayan...ninJune2008.TheannouncementwasmadebySheilaSkyKassl...irstmajorfundraiser. ,, Thefoundationhelditsfir...ClubinBloomfieldHills,Mich.Guestsheardfromspeakers...
Breaking Medicine News(10 mins):Health News:Oklahoma Thunder Inserts HydroWorx into Line-Up at Integris Health Center 2Health News:Oklahoma Thunder Inserts HydroWorx into Line-Up at Integris Health Center 3Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:Paying Tribute to Boxer Francisco 'Paco' Rodriguez 2Health News:Sky Foundation, Inc. Raises More Than $100,000 to Find a Test for Early Detection of Pancreatic Cancer 2
...idiopathic pulmonary fibrosis. This disease is inc...g// in the lungs, which often leads to a lung tran...journal Chest, the research shows that more than h...test to measure lung function. "Over five mi...
... communication channel between the human brain and...of electrophysiological signals like the Electroen...e BCI system detects such changes and transforms i... enable completely paralyzed patients (locked-in s...
..., the third leading cause of infant death, may be ... to an article in Nursing for Women’s Health, neon...parents on the potential benefits of using a pacif...pacifier use be encouraged for children less than ...
...t and dairy products from cloned animals// are saf...ty (EFSA) was asked by the European Commission to ... At present, there is no specific regulati...s from cloned animals were safe. It has pu...
...r in Bihar with seven new cases detected this year... a state that has vowed to eradicate it by 2007-en...o cases surfaced in the state till the first week ...wo in Muzaffarpur and one each in Supaul and Rohta...
... serious risks of injury and even death from needl... As lung cancer is the leading cause of cancer de...hat early detection and treatment could save lives...d the study, said conclusively, “We don’t think th...
Other Medicine News:Health News:Viagra Helps Patients With Idiopathic Pulmonary Fibrosis 2Health News:EU to Look at Cloned Meat Safety 2Health News:Seven Polio Cases Detected in Bihar 2Health News:CT Scans may Not Benefit Lung Cancer Patients 2
AP250 Auto Chart Projector
ResMed VPAP III ST
...entilator is a blower-based, bi-level positive pre...ously breathing patients weighing 30 kg or more. T... insufficiency and/or obstructive sleep apnea in t...The KnightStar 330 Ventilator includes a 3-30 cm H...
GoodKnight® 425 Bi-Level® Device
Medicine Products: